NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ): Valuation in Focus After Major Epilepsy Drug Deal and Leadership Change
Jazz Pharmaceuticals (JAZZ) just turned heads with a major licensing agreement: the company secured exclusive worldwide rights to develop and commercialize Saniona’s SAN2355, a preclinical therapy designed to address key shortcomings in existing epilepsy treatments. This move, coming on the heels of bringing in new CEO Renee Gala, could signal renewed ambition as Jazz looks to build out its neurological pipeline and position itself in the race for next-generation therapeutics. Investors...